Notícias e Atividades da Altamira Therapeutics
Presença
Sede: Suíça
Altamira Therapeutics é uma empresa listada sob o símbolo EARS (CH).
Executivos
Veja o organograma con seus 8 executivos principais
Biografias mais buscadas da Altamira Therapeutics
- Thomas Meyer, Chief Executive Officer and Chairman of the Board
- Alain Munoz, Director
- Dominik Lysek, Director
Recentes movimentos de executivos em Altamira Therapeutics
- Mario Barbieri, Head, Finance and Administration, deixou a Companhia (Notícia publicada em 26 de junho de 2026).
Criar um alerta
para seguir os movimentos de executivos da Altamira Therapeutics.
Farmacêutica
Altamira Therapeutics possui 1.920 concorrentes concorrentes Sanofi (França), Moderna (Estados Unidos) e Eli Lilly (Estados Unidos).
Popular M&A news in Farmacêutica
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado em 17 de julho de 2026).
- Agenus acaba de anunciar uma arrecadação de fundos de 340 milhões de dólares. (publicado em 17 de julho de 2026).
- GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Altamira Therapeutics
- Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business | Altamira Therapeutics
- Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine | Altamira Therapeutics
- Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis | Altamira Therapeutics
- Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results | Altamira Therapeutics
- Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th | Altamira Therapeutics
- Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 | Altamira Therapeutics
- Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia | Altamira Therapeutics
- Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal | Altamira Therapeutics
- Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering | Altamira Therapeutics
- Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration | Altamira Therapeutics
- View more press releases Close
Redes sociais sobre Altamira Therapeutics
- Altamira Therapeutics na Wikipedia, Google News e Yahoo Finance
- Altamira Therapeutics na LinkedIn, X (Twitter) e YouTube
